271 related articles for article (PubMed ID: 33426566)
1. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
Tsiogka A; Bauer JW; Patsatsi A
Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
[TBL] [Abstract][Full Text] [Related]
2. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
Lopez AT; Geskin L
Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
4. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
[TBL] [Abstract][Full Text] [Related]
5. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
Mazumder A; Darji K; Smith K; Guo M
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
[TBL] [Abstract][Full Text] [Related]
6. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.
Kosche C; Owen JL; Sadowsky LM; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735006
[TBL] [Abstract][Full Text] [Related]
7. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
8. Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.
Zumelzu C; Alexandre M; Le Roux C; Weber P; Guyot A; Levy A; Aucouturier F; Mignot-Grootenboer S; Caux F; Maubec E; Prost-Squarcioni C
Front Med (Lausanne); 2018; 5():268. PubMed ID: 30320114
[TBL] [Abstract][Full Text] [Related]
9. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
10. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
11. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
12. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
[TBL] [Abstract][Full Text] [Related]
13. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
[TBL] [Abstract][Full Text] [Related]
15. Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients.
Yun JSW; Chan OB; Goh M; McCormack CJ
Australas J Dermatol; 2023 Feb; 64(1):131-137. PubMed ID: 36514287
[TBL] [Abstract][Full Text] [Related]
16. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.
Gresham LM; Kirchhof MG
SAGE Open Med Case Rep; 2023; 11():2050313X231160926. PubMed ID: 36968984
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of Drug-Induced Pemphigoid.
Verheyden MJ; Bilgic A; Murrell DF
Acta Derm Venereol; 2020 Aug; 100(15):adv00224. PubMed ID: 32176310
[TBL] [Abstract][Full Text] [Related]
18. Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.
Sabaté Ortega J; Fort Culillas R; Escoda Garcia M; Vásquez-Dongo CA; Sala González N
Curr Oncol; 2023 Aug; 30(9):7802-7809. PubMed ID: 37754481
[TBL] [Abstract][Full Text] [Related]
19. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
Merli M; Accorinti M; Romagnuolo M; Marzano A; Di Zenzo G; Moro F; Antiga E; Maglie R; Cozzani E; Parodi A; Gasparini G; Sollena P; De Simone C; Caproni M; Pisano L; Fattore D; Balestri R; Sena P; Vezzoli P; Teoli M; Ardigò M; Vassallo C; Michelerio A; Satta RR; Dika E; Melotti B; Ribero S; Quaglino P
Front Med (Lausanne); 2023; 10():1208418. PubMed ID: 37547602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
